Skip to content

Clinical trial on the virucidal activity of different oral antiseptics against respiratory viruses.

Status
Not yet recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515939-30-01
Acronym
OralAntiseptic_Virus
Enrollment
810
Registered
2025-04-14
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory diseases

Brief summary

Viral load in the salivary samples collected from each of the patients at the different times of application of the mouthwashes., D/T ratio (where D is the amount of nucleoprotein with the PBS solution and T is the amount of nucleoprotein with the lytic solution), which represents the reciprocal relationship between the enveloped nucleoprotein and the total nucleoprotein (I/T) and corresponds to I/T = 1 -D/T. In this case, the I/T ratio serves to quantify the proportion of intact viral particles.

Interventions

DRUGBetadine bucal 100 mg/ml solución bucal
DRUGAgua oxigenada Foret 3 % solución cutánea y concentrado para solución bucal
DRUGAgua para preparaciones inyectables Meinsol
DRUGdisolvente para uso parenteral

Sponsors

Fundacion Instituto De Investigacion Sanitaria De Santiago De Compostela
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Viral load in the salivary samples collected from each of the patients at the different times of application of the mouthwashes., D/T ratio (where D is the amount of nucleoprotein with the PBS solution and T is the amount of nucleoprotein with the lytic solution), which represents the reciprocal relationship between the enveloped nucleoprotein and the total nucleoprotein (I/T) and corresponds to I/T = 1 -D/T. In this case, the I/T ratio serves to quantify the proportion of intact viral particles.

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026